Provided By PR Newswire
Last update: Jun 22, 2025
NEW YORK, June 22, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of PTC Therapeutics, Inc. ("PTC" or the "Company") (NASDAQ: PTCT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Read more at prnewswire.com63.02
+1.01 (+1.63%)
Find more stocks in the Stock Screener